Nomura Maintains 'Buy' Ratings on Zydus Lifesciences and Cipla with Raised Targets
Nomura has maintained 'Buy' ratings on Zydus Lifesciences and Cipla, raising target prices to Rs 1,450 and Rs 1,510 respectively. Zydus is expanding through increased investments and acquisitions across India, international markets, and the US, aiming for sustained EBITDA margins by FY29. Cipla is expected to see steady growth in its One-India business, supported by partnerships and acquisitions, with an improving EBITDA margin forecasted for Q2FY27. Challenges include subdued growth in Cipla's core therapies and South African operations.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 34/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 26 Oct, 07:14 am. Other outlets followed.